Trial now
USDCAD TECHS

Stronger In a Range

AUDUSD TECHS

Weaker In A Range

US TSYS SUMMARY

Ending The Week On A Soft Note

EURJPY TECHS

Bearish Risk Growing

USDJPY TECHS

Stronger, But Still Vulnerable

US

SP500 PE Ratio vs. CPI Inflation

EQUITIES

Equity futures and US yields initially dipped on Johnson & Johnson's release of their COVID-19 vaccine candidate efficacy, with the data showing 66% effectiveness in global trial results. It appears the South African variant is dragging the headline lower, with the vaccine 72% effective in the US, 66% in Latin America but just 57% in South Africa.

  • Nonetheless, some positive signals are in the details of the release, with the vaccine candidate proving 85% effective in preventing severe disease across all regions studied, demonstrating complete protection against COVID-related hospitalization and death, 28 days post-vaccination.

Full Johnson & Johnson press release here.

MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com